Innocan Pharma Corp. has inaugurated its first new drug research and development lab at Biohouse Labs at Hadassah Medical Center in Jerusalem to accelerate the company's liposome platform technology (LPT) development. The company's development program is focused on improving and optimizing LPT characterization methods and upscaling capabilities.
Innocan believes that upscaling production capabilities will enable Innocan to move forward with the planned experiments and may serve the basis for tech transfer for GMP production -- which is a basic need to reaching clinical human trials. A staff of six people (scientists and scientific assistants) are currently working on the accelerated development of the LPT technology.
The company previously announced that prior studies of the prolonged release of cannabidiol (CBD) from the liposomes injected subcutaneously to dogs showed continuous and significant blood concentrations of CBD over at least six weeks after a single administration. These results are a significant advancement in the development of the technology, demonstrating the advantages of LPT in dogs, which may serve as a good prediction to the behaviour of LPT in humans.
"The initial results of our LPT animal trials were so promising so we decided to step it up a notch, moving towards our goal reaching commercialization and becoming worldwide leader in CBD drug development," said Iris Bincovich, chief executive officer of Innocan Pharma. "We are proud of our co-operation with The Hebrew University of Jerusalem and to be able to join-hands with Israel's leading scientific institutions."
Innocan's relationship with The Hebrew University
Innocan Israel has entered into the research and license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, with respect to the design, preparation, characterization and evaluation of CBD- (or other cannabinoid-) loaded liposomes. The research and development initiative is led by professor Chezy Barenholz, head of the Membrane and Liposome research department at The Hebrew University, which is the inventor of over 55 patent families, two of which underlie Doxil, an FDA-approved drug for breast cancer treatment. This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders. A patent was filed covering this technology on Oct. 7, 2019.
About Innocan Pharma Corp.
Innocan Pharma is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Pharma and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administered by inhalation, will be tested against a variety of lung infections.
Innocan Pharma signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administered by injection. Innocan Israel plans, together with Professor Barenholz, to test the liposome platform on several potential conditions. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful records in the pharmaceutical and technology sectors in Israel and globally.